Dermatology CE Activities

LATEST Dermatology ARTICLES

RSS Dermatology Articles
  • Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma September 12, 2022
    A phase 2, multicenter study showed that four doses of neoadjuvant cemiplimab (anti–PD-1 antibody) led to a pathological complete response in 51% of patients with locally advanced cutaneous squamous-cell carcinoma.
    Neil D. Gross, David M. Miller, Nikhil I. Khushalani, Vasu Divi, Emily S. Ruiz, Evan J. Lipson, Friedegund Meier, Yungpo B. Su, Paul L. Swiecicki, Jennifer Atlas, Jessica L. Geiger, Axel Hauschild, Jennifer H. Choe, Brett G.M. Hughes, Dirk Schadendorf, Vishal A. Patel, Jade Homsi, Janis M. Taube, Annette M. Lim, Renata Ferrarotto, Howard L. Kaufman, Frank Seebach, Israel Lowy, Suk-Young Yoo, Melissa Mathias, Keilah Fenech, Hyunsil Han, Matthew G. Fury, Danny Rischin
  • Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus September 8, 2022
    In adults with SLE, litifilimab, a subcutaneously administered monoclonal antibody against BDCA2 on plasmacytoid dendritic cells, reduced the number of swollen and painful joints at 24 weeks.
    Richard A. Furie, Ronald F. van Vollenhoven, Kenneth Kalunian, Sandra Navarra, Juanita Romero-Diaz, Victoria P. Werth, Xiaobi Huang, George Clark, Hua Carroll, Adam Meyers, Cristina Musselli, Catherine Barbey, Nathalie Franchimont, the LILAC Trial Investigators
  • Progress toward Better Treatment of Lupus September 8, 2022
    Systemic lupus erythematosus (SLE) is an inflammatory, multisystem autoimmune disease of unknown cause that has protean clinical and laboratory manifestations along with a variable course and prognosis.1 Approximately 200,000 patients in the United States currently meet the diagnostic criteria for lupus, but up to 500,000 have features that...
    Daniel J. Wallace

RMEI LIGHTNING TALKS

View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.

Previously Published CE Activities